165 related articles for article (PubMed ID: 18094967)
1. In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1.
Gravekamp C; Leal B; Denny A; Bahar R; Lampkin S; Castro F; Kim SH; Moore D; Reddick R
Cancer Immunol Immunother; 2008 Jul; 57(7):1067-77. PubMed ID: 18094967
[TBL] [Abstract][Full Text] [Related]
2. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice.
Nagai E; Ogawa T; Kielian T; Ikubo A; Suzuki T
Cancer Immunol Immunother; 1998 Oct; 47(2):72-80. PubMed ID: 9769115
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with Mage-b DNA induces CD8 T-cell responses at young but not old age in mice with metastatic breast cancer.
Castro F; Leal B; Denny A; Bahar R; Lampkin S; Reddick R; Lu S; Gravekamp C
Br J Cancer; 2009 Oct; 101(8):1329-37. PubMed ID: 19826426
[TBL] [Abstract][Full Text] [Related]
4. Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy.
Sypniewska RK; Hoflack L; Tarango M; Gauntt S; Leal BZ; Reddick RL; Gravekamp C
Breast Cancer Res Treat; 2005 May; 91(1):19-28. PubMed ID: 15868428
[TBL] [Abstract][Full Text] [Related]
5. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1.
Büeler H; Mulligan RC
Mol Med; 1996 Sep; 2(5):545-55. PubMed ID: 8898371
[TBL] [Abstract][Full Text] [Related]
6. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.
Kim SH; Castro F; Gonzalez D; Maciag PC; Paterson Y; Gravekamp C
Br J Cancer; 2008 Sep; 99(5):741-9. PubMed ID: 18728665
[TBL] [Abstract][Full Text] [Related]
7. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
8. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination.
Sun X; Hodge LM; Jones HP; Tabor L; Simecka JW
Vaccine; 2002 Jan; 20(9-10):1466-74. PubMed ID: 11818167
[TBL] [Abstract][Full Text] [Related]
10. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
[TBL] [Abstract][Full Text] [Related]
11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
12. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
[TBL] [Abstract][Full Text] [Related]
13. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
14. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens.
Hsieh CL; Pang VF; Chen DS; Hwang LH
Hum Gene Ther; 1997 Nov; 8(16):1843-54. PubMed ID: 9382951
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models.
Furugaki K; Cui L; Kunisawa Y; Osada K; Shinkai K; Tanaka M; Kataoka K; Nakano K
PLoS One; 2014; 9(7):e101854. PubMed ID: 25013909
[TBL] [Abstract][Full Text] [Related]
17. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine.
Weiss WR; Ishii KJ; Hedstrom RC; Sedegah M; Ichino M; Barnhart K; Klinman DM; Hoffman SL
J Immunol; 1998 Sep; 161(5):2325-32. PubMed ID: 9725227
[TBL] [Abstract][Full Text] [Related]
18. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
McLaughlin JP; Abrams S; Kantor J; Dobrzanski MJ; Greenbaum J; Schlom J; Greiner JW
J Immunother; 1997 Nov; 20(6):449-59. PubMed ID: 9409450
[TBL] [Abstract][Full Text] [Related]
19. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
20. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
